Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Jan 06, 2018 3:09pm
115 Views
Post# 27297835

RE:RE:RE:RE:RE:RE:Who is this guy?

RE:RE:RE:RE:RE:RE:Who is this guy?
smartmichel wrote:
PoorOpinion wrote:
 

Maybe he didnt hold 6 months ago, maybe he bought the delay dip and is cashing in profits now.


You are right Pooropinion  but why he will not cash tomorrow (next trading day)? In Short Term perspective as you said, TIME is a  (probability) prime. Every second the bus doesn't arrive at the abribus increase the probability it will come next minute, hour or tomorrow. On that ST perspective, somebody must to report the selling (theorically).
This said, I don't undestrand the strategic of Short Term traders on that kind of stock. Many others stocks are born for that (volume...).


In you're analogy when he leaves the bus stop he also find fifty dollars on the sidewalk (his profits) so he can take an Uber and get where he wants to go faster.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities